|
Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90
|
March 19, 2023
|
PC3I Authors Ronac Mamtani; Melina Marmarelis |
Clinical Lung Cancer
|
|
Comment on: Premature delivery in the domestic sow in response to in utero delivery of AAV9 to fetal piglets
|
March 14, 2023
|
PC3I Authors |
Gene Therapy
|
|
Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
|
March 13, 2023
|
PC3I Authors Charu Aggarwal |
Clinical Cancer Research
|
|
Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma
|
March 10, 2023
|
PC3I Authors Melina Marmarelis |
JAMA Network Open
|
|
Patient-Oriented Tools for Communicating Lung Cancer Screening Results: The First of Many Critical Components
|
March 9, 2023
|
PC3I Authors Katharine Rendle; Anil Vachani |
Chest
|
|
Oral and emotional health experience of refugees’ in the state of Massachusetts – A mixed methods approach
|
March 9, 2023
|
PC3I Authors Tamara J. Cadet |
PLoS One
|
|
Could DNA Fragments Be the Key to Early Detection of Lung Cancer?
|
March 8, 2023
|
PC3I Authors Anil Vachani |
American Journal of Respiratory and Critical Care Medicine
|
|
Access for Cancer Caregivers to Education and Support for Shared Decision Making (ACCESS) intervention: a cluster cross-over randomised clinical trial
|
March 2, 2023
|
PC3I Authors George Demiris |
BMJ Supportive & Palliative Care
|
|
PI3king apart a rare disease with targeted therapy
|
March 2, 2023
|
PC3I Authors |
Blood
|
|
Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis
|
March 2, 2023
|
PC3I Authors Ronac Mamtani |
Journal of Cancer Research & Clinical Oncology
|
|
The Coming of Age of Nucleic Acid Vaccines during COVID-19
|
March 2, 2023
|
PC3I Authors Likhitha Kolla |
mSystems
|
|
Application of Traditional Vaccine Development Strategies to SARS-CoV-2
|
March 2, 2023
|
PC3I Authors Likhitha Kolla |
mSystems
|
|
Association Between Age and Survival Trends in Advanced Non-Small Cell Lung Cancer After Adoption of Immunotherapy
|
March 1, 2023
|
PC3I Authors Teja Voruganti |
JAMA Oncology
|
|
Adjuvant Atezolizumab Should Be Administered to All Patients With Programmed Death-Ligand 1 Expressing Surgically Resected Stage II to III NSCLC After Chemotherapy: In Favor
|
February 26, 2023
|
PC3I Authors Melina Marmarelis; Charu Aggarwal |
Journal of Thoracic Oncology
|
|
A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer
|
February 25, 2023
|
PC3I Authors Melina Marmarelis |
Clinical Lung Cancer
|
|
TP53 in AML and MDS: The new (old) kid on the block
|
February 25, 2023
|
PC3I Authors Catherine Lai |
Blood Reviews
|
|
Combining Breast Cancer Risk Prediction Models
|
February 25, 2023
|
PC3I Authors Anne Marie McCarthy |
Cancers (Basel)
|
|
Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
|
February 23, 2023
|
PC3I Authors Ramy Sedhom; Ronac Mamtani |
JAMA Oncology
|
|
Salivary cotinine level and treatment response in muscle invasive bladder cancer: A pilot study
|
February 23, 2023
|
PC3I Authors Ronac Mamtani |
BJUI Compass
|
|
Leveraging machine learning to identify acute myeloid leukemia patients and their chemotherapy regimens in an administrative database
|
February 23, 2023
|
PC3I Authors Alix Seif |
Pediatric Blood & Cancer
|
